All In Biotech

Drug Trial Radar · NCT07218926

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

May 30, 2028

Study completion Nov 29, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.

Conditions

  • Gastrointestinal Neoplasms

Interventions

  • IDRX-42Drug

    IDRX-42 will be administered.

  • SunitinibDrug

    Sunitinib will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 130 weeks

Locations

156 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona · Recruiting

  • GSK Investigational Site

    Duarte, California · Recruiting

  • GSK Investigational Site

    La Jolla, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    San Francisco, California · Recruiting

  • GSK Investigational Site

    Santa Monica, California · Recruiting

  • GSK Investigational Site

    Upland, California · Recruiting

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • GSK Investigational Site

    Jacksonville, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Orlando, Florida · Recruiting

  • GSK Investigational Site

    Tampa, Florida · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Iowa City, Iowa · Recruiting

  • GSK Investigational Site

    Overland Park, Kansas · Recruiting

  • GSK Investigational Site

    Baton Rouge, Louisiana · Recruiting

  • GSK Investigational Site

    Baltimore, Maryland · Recruiting

  • GSK Investigational Site

    Boston, Massachusetts · Recruiting

  • GSK Investigational Site

    Boston, Massachusetts · Recruiting

  • GSK Investigational Site

    Ann Arbor, Michigan · Recruiting

  • GSK Investigational Site

    Rochester, Minnesota · Recruiting

  • GSK Investigational Site

    St Louis, Missouri · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    New Hyde Park, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Rochester, New York · Recruiting

  • GSK Investigational Site

    Charlotte, North Carolina · Recruiting

  • GSK Investigational Site

    Durham, North Carolina · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Columbus, Ohio · Recruiting

  • GSK Investigational Site

    Portland, Oregon · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Pittsburgh, Pennsylvania · Recruiting

  • GSK Investigational Site

    Spartanburg, South Carolina · Recruiting

  • GSK Investigational Site

    Knoxville, Tennessee · Recruiting

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.